Clinical trials: Nausea With Vomiting Chemotherapy-Induced
Nausea and Vomiting Chemotherapy-Induced, Nausea Post Chemotherapy
Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)
Chemotherapy often causes nausea and vomiting (CINV), and this is a major problem for the children being treated for cancer. To prevent this, a combination of two substances in fixed proportion (IV NEPA) was developed.
- Trial name
- NCT06904235
- Testing
- IV NEPA (fosnetupitant/palonosetron), Reference Treatment: IV ondansetron infusion, Reference Treatment: IV fosaprepitant infusion
- Where
- 20 sites in Greece, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy-Induced Nausea and Vomiting (CINV)
Effect of Mandala Coloring on Nausea, Fatigue, and Well-Being in Chemotherapy Patients
This study aims to evaluate the effect of mandala coloring on nausea, vomiting, fatigue, and psychological well-being in cancer patients receiving chemotherapy.
- Trial name
- MANDALACHEMO (NCT07581119)
- Testing
- Mandala Coloring Intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 85 people
- Sponsor
- University of Gaziantep
Chemotherapy-Induced Nausea and Vomiting
Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric Patients
The primary objective is to evaluate the efficacy of two different doses of IV palonosetron in the prevention of chemotherapy induced nausea and vomiting in MEC and HEC patients through 120 hours after start of chemotherapy in…
- Trial name
- NCT01442376
- Testing
- Palonosetron, Ondansetron
- Where
- 67 sites in United States, Argentina and 14 more
- Volunteers
- 502 people
- Sponsor
- Helsinn Healthcare SA
Chemotherapy Induced Nausea and Vomiting Pediatric Cancer Patients
Efficacy and Safety of Fosaprepitant in Preventing Chemotherapy-induced Vomiting in Children Treated With Medium and High Emetic Chemotherapeutic Drugs
This study was a prospective, randomized, double-blind, parallel controlled clinical trial. The children who met the inclusion criteria and were treated with medium and high emetic chemotherapy drugs were randomly included in the…
- Trial name
- NCT05230654
- Testing
- Fosaprepitant
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Children's Medical Center
Chemotherapy-induced Nausea and Vomiting
Olanzapine for Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Multi-Centre Feasibility Study
Olanzapine is licensed for use in adults in Canada and in teens in the US with mental illness. It is also often used for the management of mental illness in children.
- Trial name
- NCT02129478
- Testing
- Olanzapine
- Where
- 3 sites in Canada
- Volunteers
- 15 people
- Sponsor
- The Hospital for Sick Children
Chemotherapy-induced Nausea and Vomiting
Effectiveness of Laserpuncture and Standard Antiemetic on RINVR Scores in Adolescent Patients Undergoing Chemotherapy
Chemotherapy is a common treatment for treating cancer. Chemotherapy induced nausea and vomiting (CINV) is nausea and vomiting that occurs after chemotherapy.
- Trial name
- NCT06121414
- Testing
- laserpuncture
- Where
- 2 sites in Indonesia
- Volunteers
- 58 people
- Sponsor
- Universitas Indonesia
Chemotherapy Induced Nausea and Vomiting
Pharmacokinetics and Safety of Sancuso and IV Granisetron in Pediatrics Aged 6 to 12 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 6 to 12 years.
- Trial name
- NCT01596413
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Vomiting
Study of Aprepitant (MK-0869) for Chemotherapy-Induced Nausea and Vomiting (CINV) in Adolescent Participants (MK-0869-097)
This study is being conducted to demonstrate that aprepitant (MK-0869) prevents nausea and vomiting caused by emetogenic cancer chemotherapy in adolescent participants.
- Trial name
- NCT00080444
- Testing
- aprepitant, ondansetron, dexamethasone
- Volunteers
- 50 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy-Induced Nausea and Vomiting
A Study of MK-0869 (Aprepitant) and MK-0517 (Fosaprepitant) in Pediatric Participants Receiving Chemotherapy (MK-0869-134)
This study will determine the appropriate dosing regimen of aprepitant and fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric participants from 0 months to 17 years of age.
- Trial name
- NCT00818259
- Testing
- Experimental: aprepitant, Experimental: fosaprepitant, Comparator: ondansetron
- Volunteers
- 92 people
- Sponsor
- Merck Sharp & Dohme LLC
Chemotherapy Induced Nausea and Vomiting, Quality of Life (QOL)
Vomiting Prevention in Children With Cancer
The goal of this single arm trial is to learn if a machine learning (ML) model predicting the risk of vomiting within the next 96 hours will impact vomiting outcomes in inpatient cancer pediatric patients.
- Conditions
- Chemotherapy Induced Nausea and Vomiting, Quality of Life (QOL), Pediatric Cancer
- Trial name
- NCT06886451
- Testing
- ML-based intervention
- Where
- Canada
- Volunteers
- 1,953 people
- Sponsor
- The Hospital for Sick Children
Chemotherapy-Induced Nausea and Vomiting
A Study to Evaluate the Safety and Efficacy of Aprepitant (MK0869) for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients
Aprepitant was approved in 2003. The drug works to lessen the amount of nausea and vomiting that cancer patients experience after treatment. Aprepitant has been well-studied in adults, but not in children.
- Trial name
- NCT01757210
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- West Virginia University Healthcare
Pediatric Cancer
Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Patients
The purpose is to evaluate the effectiveness and safety of fosaprepitant plus ondansetron with dexamethasone or placebo plus ondansetron with dexamethasone in preventing chemotherapy-induced nausea and vomiting (CINV) with MEC/HE…
- Trial name
- NCT04508400
- Testing
- Fosaprepitant,ondansetron, dexamethasone
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Chemotherapy Induced Nausea and Vomiting, Pediatric Cancer Patients
Comparative Study of Fosaprepitant and Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Pediatric Caner Patients
Children aged 2-12 years scheduled to receive moderately or highly emetogenic chemotherapy were randomly assigned to arm-A (fosaprepitant) or arm-B (aprepitant).
- Trial name
- NCT04873284
- Testing
- fosaprepitant, aprepitant, Granisetron plus dexamethasone
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Shanghai Children's Medical Center
Chemotherapy Induced Nausea and Vomiting
Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
The purpose of this study is to determine the feasibility of a larger trial comparing olanzapine and aprepitant and to obtain preliminary data on the effectiveness of these two medications to treat nausea and vomiting in children…
- Trial name
- NCT02097823
- Testing
- Olanzapine, Aprepitant
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Indiana University
Chemotherapy-induced Nausea and Vomiting
To Study the Safety and Effectiveness of a Granisetron Patch to Treat Chemotherapy-Induced Nausea and Vomiting (CINV)
To study the safety and effectiveness of a granisetron patch to treat Chemotherapy-Induced Nausea and Vomiting (CINV)
- Trial name
- NCT00273468
- Testing
- Granisetron
- Volunteers
- 630 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Chemotherapy Induced Nausea and Vomiting
Study to Evaluate Anti-emetic Effect of Aprepitant Versus Placebo in Children and Adolescent Receiving Chemotherapy
Chemotherapy induced nausea and vomiting (CINV) is one of the few mostly observed distressing toxicity of cancer treatment. It can occur up to 90% in case of highly emetogenic chemotherapy use.
- Trial name
- Aprepitant (NCT01402024)
- Testing
- Aprepitant
- Where
- India
- Volunteers
- 96 people
- Sponsor
- All India Institute of Medical Sciences
Chemotherapy-Induced Nausea and Vomiting
Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors
The hypothesis is that the substitution of multi-day oral aprepitant with (intravenous) IV fosaprepitant, in combination with a 5-HT3 receptor antagonists (5HT3RA) + dexamethasone will provide comparable protection from 5 day…
- Trial name
- NCT01736917
- Testing
- Fosaprepitant, Dexamethasone, 5HT3
- Where
- 4 sites in United States
- Volunteers
- 65 people
- Sponsor
- Lawrence Einhorn
Acute Leukemia
Nausea and Vomiting in Children Receiving Chemotherapeautic Monotherapy
Chemotherapy induced nausea is a common side effect for children undergoing chemotherapy. Furthermore, chemotherapy-induced vomiting is a major factor limiting quality of life during treatment reported by paediatric cancer…
- Trial name
- NCT01661413
- Where
- Canada
- Volunteers
- 88 people
- Sponsor
- The Hospital for Sick Children
Chemotherapy Induced Nausea and Vomiting
Safety and Pharmacokinetics of Sancuso and IV Granisetron in Patients Aged 2 to 5 Years
The purpose of this study is to determine the dosing strategy for adolescents aged 2 to 5 years.
- Trial name
- NCT01596426
- Testing
- Sancuso, IV granisetron
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Chemotherapy-induced Nausea and Vomiting, Pediatric Cancer
Effect of Guided Imagery on Chemotherapy-related Nausea and Vomiting
The goal of this randomized controlled study is to assess the effect of guided imagery on chemotherapy-related nausea and vomiting in pediatric oncology patients.
- Trial name
- NCT06120764
- Testing
- guided imagery
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Baskent University